Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexborneol SCHEMBL13444553 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL14236488 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL9303298 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL3507513 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL5031066 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL23849409 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| (-)-Borneol SCHEMBL839194 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Borneol SCHEMBL20576251 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL20576252 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 | |
| Dexborneol SCHEMBL115723 | 1.00 | EPHX2 (0.41) | EPHX2MAPTMAPK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1331222-A1 | Environment friendly reagents and process for halogenoalkylsulfinylation of organic compounds | VIRBAC S.A. (FR) | 2003-07-30 | — | — | EP | claimed |
| US-20250380732-A1 | AEROSOLISABLE FORMULATION | NICOVENTURES TRADING LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250241356-A1 | ORAL COMPOSITION COMPRISING RECEPTOR MODULATOR | DANIEL MICHAEL S (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4543230-A1 | AEROSOLISABLE FORMULATION | Nicoventures Trading Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240092960-A1 | FLUORINE-FREE DYNAMIC WATER REPELLENTS WITH OIL-REPELLENT PROPERTIES, WATER-REPELLENT ARTICLES, AND METHODS OF MAKING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY | 2024-03-21 | — | — | US | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4301795-A1 | FLUORINE-FREE DYNAMIC WATER REPELLENTS WITH OIL-REPELLENT PROPERTIES, WATER-REPELLENT ARTICLES, AND METHODS OF MAKING THE SAME | 3M Innovative Properties Company (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-1364933-A1 | OPTICAL RESOLVER AND METHOD OF OPTICALLY RESOLVING ALCOHOL WITH THE SAME | Zeon Corporation (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1331222-A1 | Environment friendly reagents and process for halogenoalkylsulfinylation of organic compounds | VIRBAC S.A. (FR) | 2003-07-30 | — | — | EP | disclosed |
| US-20030031583-A1 | Vapor-phase corrosion inhibitors and method of preparing same | EXCOR KORROSIONSFORSCHUNG GMBH (DE) | 2003-02-13 | — | — | US | disclosed |
| US-5637601-A | ANTIPERSPIRANT, MYDRIATIC, ANTISECRETORY AGENTS | UNIVERSITY OF FLORIDA (US) | 1997-06-10 | — | — | US | disclosed |
| US-5618826-A | Anticholinergic compounds, compositions and methods of treatment | UNIVERSITY OF FLORIDA (US) | 1997-04-08 | — | — | US | disclosed |
| US-5610188-A | MYDRIATICS, ANTIPERSPIRANTS | UNIVERSITY OF FLORIDA (US) | 1997-03-11 | — | — | US | disclosed |
| US-5418244-A | Antiperspirants, mydriatic | UNIVERSITY OF FLORIDA (US) | 1995-05-23 | — | — | US | disclosed |
| US-5258388-A | Antisecretory agents, mydriatic agents and antiperspirants | UNIVERSITY OF FLORIDA (US) | 1993-11-02 | — | — | US | disclosed |
| US-5223528-A | Antisecretory agents, mydriatics, antiperspirants | UNIVERSITY OF FLORIDA (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1991018890-A1 | BICYCLIC CHIRAL COMPOUNDS | THE BRITISH PETROLEUM COMPANY PLC (GB) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | EPHX2 2387/4885MAPT 3403/4885MAPK1 4847/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | EPHX2 2387/4885MAPT 3403/4885MAPK1 4847/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | EPHX2 2387/4885MAPT 3403/4885MAPK1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.